BridgeBio Pharma, Inc.BBIO
Market cap
$14.5B
P/E ratio
| 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | - | - | 6 | 7 | 6 | 6 |
| Stock-based compensation | 21 | 58 | 100 | 92 | 109 | 96 |
| Cash from operations | -254 | -400 | -498 | -419 | -528 | -521 |
| Capital expenditures | -3 | -8 | -13 | -5 | -1 | -1 |
| Cash from investing | -217 | -53 | -201 | 453 | 54 | 61 |
| Payments for dividends | 1 | - | - | - | - | - |
| Repurchases of common stock | - | 75 | 200 | - | - | - |
| Repayments of term debt | - | - | 124 | 20 | - | 473 |
| Cash from financing | 399 | 447 | 736 | -13 | 452 | 748 |
| Free cash flow | ||||||
| FCF margin (%) |